Berita
Biotech Drugs\' Generic Future Debated
IFPMA Press Review 2/10/2005 Biotech Drugs' Generic Future Debated The Washington Post   MALVERN, Pa. (USA), 2/10/2005 - To more than half a million patients suffering from rheumatoid arthritis or Crohn's disease, Remicade has brought life-changing treatment and relief. But the drug, ...
IFPMA Press Review 2/10/2005

Biotech Drugs' Generic Future Debated
 
The Washington Post
 
MALVERN, Pa. (USA), 2/10/2005 - To more than half a million patients suffering from rheumatoid arthritis or Crohn's disease, Remicade has brought life-changing treatment and relief.

But the drug, a genetically engineered protein produced not by chemistry but by living cells in a manufacturing process that requires 310 discrete steps, also brings a heavy financial burden. The manufacturer estimates that each patient will pay $14,000 to $16,000 a year for Remicade, and that people generally will take it indefinitely.

bersambung ke halaman 2 ( 1 2 3 4 5 6 7 8 9 )
Kembali         Cetak
Isi Komentar Anda
Nama
Email
Komentar
Mak [600] Karakter
Verifikasi kode